Biodexa Pharmaceuticals Plc
No SEC Form 4 filings for $BDRX in the last 30 days.
See all $BDRX insider activity →RH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).
Biodexa Pharmaceuticals (BDRX) has enrolled 87 of 168 planned patients in its Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP), with sites in the U.S. and Europe. The trial aims to evaluate eRapa, a rapamycin-based treatment, with a $20M grant supporting the program. BDRX stock is up 6.62% to $23.82.
Biodexa Pharmaceuticals PLC has issued a letter to shareholders detailing proposals to reorganize the company’s share capital at the upcoming Annual General Meeting. These proposals aim to rationalize the share capital by reducing the number of ordinary shares without affecting shareholders' rights, percentage ownership, or the number of American Depositary Shares (ADSs) outstanding. The changes involve a reverse split, subdivision, redesignation of shares, and an adjustment to the ordinary share/ADS ratio, all recommended by the Board.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BDRX (Biodexa Pharmaceuticals Plc). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BDRX coverage spans financial news, earnings and technology.
Recovery suggests short covering and possible positive news.
Recruitment progress reduces execution risk and may boost investor confidence ahead of upcoming futility analysis.
Biodexa Pharmaceuticals PLC plans to reorganize its share capital through a reverse split, subdivision, and redesignation, aiming to rationalize share structure without affecting ownership rights.
Biodexa plans a significant capital reorganization involving a reverse stock split and share ratio change, aiming to rationalize share capital without diluting shareholders' ownership.
Biodexa Pharmaceuticals experienced a 3.67% decline in after-hours trading despite a significant gain during regular hours, indicating potential profit-taking or market correction.
AlphAI scores every news story that mentions BDRX with an AI model for sentiment and relevance, and aggregates insider trades from Biodexa Pharmaceuticals Plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
RH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).
3 min readBiodexa Pharmaceuticals (BDRX) has enrolled 87 of 168 planned patients in its Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP), with sites in the U.S. and Europe. The trial aims to evaluate eRapa, a rapamycin-based treatment, with a $20M grant supporting the program. BDRX stock is up 6.62% to $23.82.
2 min readBiodexa Pharmaceuticals PLC has issued a letter to shareholders detailing proposals to reorganize the company’s share capital at the upcoming Annual General Meeting. These proposals aim to rationalize the share capital by reducing the number of ordinary shares without affecting shareholders' rights, percentage ownership, or the number of American Depositary Shares (ADSs) outstanding. The changes involve a reverse split, subdivision, redesignation of shares, and an adjustment to the ordinary share/ADS ratio, all recommended by the Board.
2 min readBiodexa Pharmaceuticals plans a significant capital reorganization at its June 17, 2026 AGM, including a 10,000:1 reverse stock split of its ordinary shares and a change in the ordinary share/ADS ratio from 500,000:1 to 50:1. This move is intended to rationalize the company's share capital and administration without affecting the number of American Depositary Shares (ADSs) held, shareholders' percentage ownership, or their rights. The proposal also involves creating new E deferred shares with negligible rights, with the changes being inter-conditional and effective on June 18, 2026, if approved.
4 min readBiodexa Pharmaceuticals PLC-ADR ( NASDAQ:BDRX ) saw its stock fall 3.67% to $10.50 during after-hours trading on Thursday. Check out the current price of BDRX stock here.
2 min readBiodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min readShares of Intuit Inc. INTU rose sharply in today's pre-market after the company reported stronger-than-expected third-quarter financial results and raised its full-year guidance. Intuit reported third-quarter revenue of $7.75 billion, beating analyst estimates of $7.56 billion, according to ...
3 min read
